Trial for novel CGRP migraine medicine gleans positive results
The first pill designed to directly block calcitonin gene-related peptide…
The first pill designed to directly block calcitonin gene-related peptide (CGRP), a protein released during a migraine attack, has demonstrated positive evidence in AbbVie’s trial investigating its efficacy in the prodrome phase.